Association between Ras association domain family 1A promoter methylation and hepatocellular carcinoma: A meta-analysis

World Journal of Gastroenterology

Volumn 19, Issue 41, 2013, Pages 7189-7196

  Zhao, Ze Hua ^a   Fan, Yu Chen ^a,b   Yang, Yang ^a   Wang, Kai ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Biomarker; Diagnostic sensitivity; Diagnostic specificity; Hepatocellular carcinoma; Methylation; Ras association domain family 1A

Indexed keywords

ALPHA FETOPROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN METHYLATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; CHRONIC LIVER DISEASE; DIAGNOSTIC VALUE; DNA METHYLATION; GENETIC ASSOCIATION; MEDICAL LITERATURE; PUBLISHING; QUALITY CONTROL; SYSTEMATIC REVIEW;

BIOMARKER; DIAGNOSTIC SENSITIVITY; DIAGNOSTIC SPECIFICITY; HEPATOCELLULAR CARCINOMA; METHYLATION; RAS ASSOCIATION DOMAIN FAMILY 1A;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DNA METHYLATION; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; LIKELIHOOD FUNCTIONS; LIVER NEOPLASMS; ODDS RATIO; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; ROC CURVE; TUMOR SUPPRESSOR PROTEINS;

EID: 84887551412     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i41.7189     Document Type: Article

References (39)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255 [PMID: 22353262 DOI: 10.1016/ S0140-6736(11)61347-0]
2. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M, Trevisani F. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101: 524-532 [PMID: 16542289 DOI: 10.1111/ j.1572-0241.2006.00443.x]
3. Tischoff I, Tannapfe A. DNA methylation in hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1741-1748 [PMID: 18350605 DOI: 10.3748/wjg.14.1741]
4. Herath NI, Leggett BA, MacDonald GA. Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol 2006; 21: 15-21 [PMID: 16706806 DOI: 10.1111/j.1440-1746.2005.04043.x]
5. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a highthroughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28: E32 [PMID: 10734209 DOI: 10.1093/nar/ 28.8.e32]
6. Shivapurkar N, Gazdar AF. DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med 2010; 10: 123-132 [PMID: 20196733 DOI: 10.2174/1566524107 90963303]
7. Summers T, Langan RC, Nissan A, Brücher BL, Bilchik AJ, Protic M, Daumer M, Avital I, Stojadinovic A. Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection. J Cancer 2013; 4: 210-216 [PMID: 23459561 DOI: 10.7150/jca.5839]
8. Ramzy II, Omran DA, Hamad O, Shaker O, Abboud A. Evaluation of serum LINE-1 hypomethylation as a prognostic marker for hepatocellular carcinoma. Arab J Gastroenterol 2011; 12: 139-142 [PMID: 22055592 DOI: 10.1016/ j.ajg.2011.07.002]
9. Pike BL, Guerry P, Poly F. Global Distribution of Campylobacter jejuni Penner Serotypes: A Systematic Review. PLoS One 2013; 8: e67375 [PMID: 23826280 DOI: 10.1371/journal. pone.0067195]
10. Majchrzak-Celińska A, Paluszczak J, Kleszcz R, Magiera M, Barciszewska AM, Nowak S, Baer-Dubowska W. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. J Appl Genet 2013; 54: 335-344 [PMID: 23661397 DOI: 10.1007/s13353-013-0149-x]
11. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta 2007; 1775: 181-232 [PMID: 17137717 DOI: 10.1016/j.bbcan.2006.10.001]
12. Danese E, Minicozzi AM, Benati M, Montagnana M, Paviati E, Salvagno GL, Gusella M, Pasini F, Guidi GC, Lippi G. Epigenetic alteration: new insights moving from tissue to plasma-the example of PCDH10 promoter methylation in colorectal cancer. Br J Cancer 2013; 109: 807-813 [PMID: 23839493 DOI: 10.1038/bjc.2013.351]
13. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005; 65: 3497-3508 [PMID: 15867337 DOI: 10.1158/0008-5472.CAN-04-4088]
14. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007; 120: 3163-3172 [PMID: 17878233 DOI: 10.1242/jcs.010389]
15. van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 2007; 1776: 58-85 [PMID: 17692468 DOI: 10.1016/j.bbcan.2007.06.003]
16. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-536 [PMID: 22007046 DOI: 10.7326/0003-4819-155-8-201110180-00009]
17. Devillé WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, Bezemer PD. Conducting sys-tematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002; 2: 9 [PMID: 12097142 DOI: 10.1186/1471-2288-2-9]
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188 [PMID: 3802833 DOI: 10.1016/0197-2456(86)90046-2]
19. Rosman AS, Korsten MA. Application of summary receiver operating characteristics (sROC) analysis to diagnostic clinical testing. Adv Med Sci 2007; 52: 76-82 [PMID: 18217394]
20. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002; 21: 1237-1256 [PMID: 12111876 DOI: 10.1002/ sim.1099]
21. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882-893 [PMID: 16085191 DOI: 10.1016/ j.jclinepi.2005.01.016]
22. Chan KC, Lai PB, Mok TS, Chan HL, Ding C, Yeung SW, Lo YM. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 2008; 54: 1528-1536 [PMID: 18653827 DOI: 10.1373/ clinchem.2008.104653]
23. Chang H, Yi B, Li L, Zhang HY, Sun F, Dong SQ, Cao Y. Methylation of tumor associated genes in tissue and plasma samples from liver disease patients. Exp Mol Pathol 2008; 85: 96-100 [PMID: 18691570 DOI: 10.1016/j.yexmp.2008.07.001]
24. Maurizio MS, Fracanzani AL, Tavazzi D, Cespiati A, Bertelli C, Bignamini D, Valenti L, Fargion SR. Aberrant methylation of oncosuppressor genes detected in the peripheral blood of patients with chronic hepatitis C and hepatocellular carcinoma. J Hepatol 2011; 54 Suppl 1: S107 [DOI: 10.1016/S0168-8278(11)60262-6]
25. Mohamed NA, Swify EM, Amin NF, Soliman MM, Tag-Eldin LM, Elsherbiny NM. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C? Arab J Gastroenterol 2012; 13: 111-115 [PMID: 23122451 DOI: 10.1016/ j.ajg.2012.06.009]
26. Azab NI, Abd El Kariem HM, Mowafi T, Fouad HF, El Abd AM. Blood Ras-association domain family 1A gene methylation status in some liver diseases. Life Sci J 2011; 8: 531-539
27. Zhang YJ, Wu HC, Shen J, Ahsan H, Tsai WY, Yang HI, Wang LY, Chen SY, Chen CJ, Santella RM. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 2007; 13: 2378-2384 [PMID: 17438096 DOI: 10.1158/1078-0432. CCR-06-1900]
28. Huang ZH, Hu Y, Hua D, Wu YY, Song MX, Cheng ZH. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp Mol Pathol 2011; 91: 702-707 [PMID: 21884695 DOI: 10.1016/j.yexmp.2011.08.004]
29. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-1573 [PMID: 12111920 DOI: 10.1002/sim.1187]
30. Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol 2013; 19: 339-346 [PMID: 23372355 DOI: 10.3748/wjg.v19.i3.339]
31. Carey E, Carey WD. Noninvasive tests for liver disease, fibrosis, and cirrhosis: Is liver biopsy obsolete? Cleve Clin J Med 2010; 77: 519-527 [PMID: 20682514 DOI: 10.3949/ ccjm.77a.09138]
32. Zhang X, Li HM, Liu Z, Zhou G, Zhang Q, Zhang T, Zhang J, Zhang C. Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma. J Gastroenterol 2013; 48: 132-143 [PMID: 22766745 DOI: 10.1007/s00535-012-0621-0]
33. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826 [PMID: 8790415 DOI: 10.1073/pnas.93.18.9821]
34. Harrison A, Parle-McDermott A. DNA methylation: a timeline of methods and applications. Front Genet 2011; 2: 74 [PMID: 22303369 DOI: 10.3389/fgene.2011.00074]
35. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012; 13: 679-692 [PMID: 22945394 DOI: 10.1038/nrg3270]
36. How Kit A, Nielsen HM, Tost J. DNA methylation based biomarkers: practical considerations and applications. Biochimie 2012; 94: 2314-2337 [PMID: 22847185 DOI: 10.1016/ j.biochi.2012.07.014]
37. Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med 2001; 20: 3625-3633 [PMID: 11746342 DOI: 10.1002/ sim.1091]
38. Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol 2007; 40: 142-150 [PMID: 17394762 DOI: 10.5483/BMBRep. 2007.40.2.142]
39. Ushijima T, Nakajima T, Maekita T. DNA methylation as a marker for the past and future. J Gastroenterol 2006; 41: 401-407 [PMID: 16799880 DOI: 10.1007/s00535-006-1846-6]